Earnings Summary

Pyxis Oncology, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2023. On a quarterly growth basis, Pyxis Oncology, Inc. has generated NaN% jump in its revenue since last 3-months.

Pyxis Oncology, Inc.’s net profit fell -168.15% since last year same period to $-15.6Mn in the Q4 2023. On a quarterly growth basis, Pyxis Oncology, Inc. has generated 32.33% jump in its net profits since last 3-months.

Pyxis Oncology, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2023. On a quarterly growth basis, Pyxis Oncology, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Pyxis Oncology, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.24 - a 48.94% jump from last quarter’s estimates.

Pyxis Oncology, Inc.’s earning per share (EPS) estimates for the current year stand at -0.24.

Pyxis Oncology, Inc.’s earning per share (EPS) jumped 67.33% since last year same period to -0.33 in the Q4 2023. This indicates that the Pyxis Oncology, Inc. has generated 67.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Pyxis Oncology, Inc.’s return on assets (ROA) stands at -0.26.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Pyxis Oncology, Inc.’s return on equity (ROE) stands at -0.52.